These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15050003)

  • 1. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.
    So AI; Bowden M; Gleave M
    BJU Int; 2004 Apr; 93(6):845-50. PubMed ID: 15050003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.
    Gleave ME; Sato N; Goldenberg SL; Stothers L; Bruchovsky N; Sullivan LD
    J Urol; 1997 May; 157(5):1727-30. PubMed ID: 9112514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H; Tolcher A; Gleave ME
    Cancer Res; 1999 Aug; 59(16):4030-4. PubMed ID: 10463603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
    Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P; Lindahl C; Bergh A
    Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer.
    Zhang Z; Xu Q; Huang X; Yang J; Xu Y; Zhang G
    Int J Clin Exp Pathol; 2015; 8(9):10283-93. PubMed ID: 26617736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adjuvant endocrine and adjuvant chemoendocrine therapies on metastasis of androgen-dependent Shionogi carcinoma 115.
    Yoshikawa T; Kitamura Y; Uchida N; Yamaguchi K; Matsumoto K
    Cancer Res; 1983 Oct; 43(10):4525-9. PubMed ID: 6883315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence.
    Myers RB; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
    J Urol; 2001 Mar; 165(3):1027-32. PubMed ID: 11176534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Johnson MA; Iversen P; Schwier P; Corn AL; Sandusky G; Graff J; Neubauer BL
    Prostate; 2005 Mar; 62(4):322-38. PubMed ID: 15389779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate.
    Landström M; Damber JE; Bergh A
    Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.
    Tang Y; Wang L; Goloubeva O; Khan MA; Zhang B; Hussain A
    Clin Cancer Res; 2008 May; 14(10):2936-43. PubMed ID: 18483360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
    Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen suppressed apoptosis is modified in p53 deficient mice.
    Colombel M; Radvanyi F; Blanche M; Abbou C; Buttyan R; Donehower LA; Chopin D; Thiery JP
    Oncogene; 1995 Apr; 10(7):1269-74. PubMed ID: 7731676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the androgen levels in the ventral prostate of spontaneously hypertensive rats after castration.
    Hu M; Xin D; Chen J; Sun G; Wang Y; Na Y
    BJU Int; 2009 Aug; 104(3):406-11. PubMed ID: 19239443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.